The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Targeting CALR with immunotherapy in MPNs
Johannes Foßelteder, Medical University of Graz, Graz, Austria, comments on the potential of targeting calreticulin (CALR)-mutated myeloproliferative neoplasm (MPN) progenitors with a neoepitope-directed monoclonal antibody and with T-cells engineered to target CALR. Recent evidence from experiments in in vitro and in vivo models has shown that monoclonal antibodies and T-cells engineered to target CALR induce efficient killing of mutant cells. This interview took place virtually.
